Xtandi 40 MG capsule 120S
Ended Awarded
- Contract number
- SPE2DR26FSBZ6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $38,298
Award facts
- Contract value 100% obligated
- $38,298.06 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $38,298.06 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This delivery order, issued on November 14, 2025, with an ultimate completion date of November 17, 2025, was awarded without a set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. The award falls under the company's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy that positions multiple regional prime vendor contractors to supply the Department of Defense with pharmaceutical products.
DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, leveraging its established performance across diverse therapeutic categories to fulfill recurring medical supply needs for military healthcare facilities worldwide. The parent contract, designated SPE2DR and awarded on November 13, 2025, carries a $499,999,999 ceiling value and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. The company's extensive product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, with delivery orders ranging from minimal purchases to significant awards exceeding $115,000, all funded exclusively by the Defense Logistics Agency with no identified subcontractor relationships.
Quick answers
Who was awarded contract SPE2DR26FSBZ6?
SPE2DR26FSBZ6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 14, 2025.
How much is contract SPE2DR26FSBZ6 worth?
The government has obligated $38,298 on SPE2DR26FSBZ6.
Is contract SPE2DR26FSBZ6 an order under another contract?
Yes. SPE2DR26FSBZ6 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.
Was contract SPE2DR26FSBZ6 competed?
The extent of competition for SPE2DR26FSBZ6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award